CNS Drugs

, Volume 15, Issue 11, pp 831–837 | Cite as

Autism and Measles-Mumps-Rubella Vaccination

Controversy Laid to Rest?
Current Opinion

Abstract

It has been suggested that vaccination, particularly with measles-mumps-rubella (MMR) vaccine, may be related to the development of autism. The main evidence for a possible association is that the prevalence of autism has been increasing at the same time that infant vaccination coverage has increased, and that in some cases there is an apparent temporal association in which autistic characteristics are first noted shortly after vaccination. Although the prevalence of autism and similar disorders appears to have increased recently, it is not clear if this is an actual increase or the result of increased recognition and changes in diagnostic criteria. The apparent onset of autism in close proximity to vaccination may be a coincidental temporal association. The clinical evidence in support of an association derives from a series of 12 patients with inflammatory bowel conditions and regressive developmental disorders, mostly autism. The possibility that measles vaccine may cause autism through a persistent bowel infection has generated much interest, since it provides a possible biological mechanism. Epidemiological studies, however, have not found an association between MMR vaccination and autism. The epidemiological findings are consistent with current understanding of the pathogenesis of autism, which has a strong genetic component and in which the neurological defects probably occur early in embryonic development. It seems unlikely that a vaccination that is given after birth could cause autism. A minority of cases of autism may have onset after 1 year of age (regressive autism), but the single epidemiological study that included such cases did not find an association with MMR vaccination. Currently, the weight of the available epidemiological and related evidence does not support a causal association between MMR vaccine, or any other vaccine or vaccine constituent, and autism.

References

  1. 1.
    Wakefield AJ, Murch S, Anthony A, et al. Ileal lymphoid nodular hyperplasia, non-specific colitis, and regressive developmental disorder in children. Lancet 1998; 351: 637–41PubMedCrossRefGoogle Scholar
  2. 2.
    Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet 1998; 351: 611–2PubMedCrossRefGoogle Scholar
  3. 3.
    Bignall J. UK experts convinced of safety of MMR. Lancet 1998; 351: 966Google Scholar
  4. 4.
    Chadwick N, Bruce IJ, Schepelmann S, et al. Measles virus DNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcriptase followed by polymerase chain reaction. J Med Virol 1998; 55: 305–11PubMedCrossRefGoogle Scholar
  5. 5.
    Montgomery SM, Morris DL, Pounder RE, et al. Paramyxo-virus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology 1999; 161: 796–803CrossRefGoogle Scholar
  6. 6.
    Afzal MA, Minor PD, Begley J, et al. Absence of measles-virus genome in inflammatory bowel disease. Lancet 1998; 351: 646PubMedCrossRefGoogle Scholar
  7. 7.
    Iizuka M, Nakagomi O, Chiba M, et al. Absence of measles virus in Crohn’s disease. Lancet 1995; 345: 199PubMedGoogle Scholar
  8. 8.
    Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Arch Pediatr Adolesc Med 2001; 155: 354–9PubMedGoogle Scholar
  9. 9.
    Wakefield AJ, Anthony A, Murch S, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000; 95: 2285–95PubMedCrossRefGoogle Scholar
  10. 10.
    Kawashimi H, Takayuki M, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000; 45: 723–9CrossRefGoogle Scholar
  11. 11.
    O’Leary JJ, Uhimann V, Wakefield AJ. Measles virus and autism. Lancet 2000; 356: 772PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026–9PubMedCrossRefGoogle Scholar
  13. 13.
    Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19: 3632–5PubMedCrossRefGoogle Scholar
  14. 14.
    Gillberg C, Heijbel H. MMR and autism. Autism 1998; 2: 423–4CrossRefGoogle Scholar
  15. 15.
    Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460–3PubMedCrossRefGoogle Scholar
  16. 16.
    Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285: 1183–5PubMedCrossRefGoogle Scholar
  17. 17.
    Rodier PM, Hyman SL. Early environmental factors in autism. MRDD Res Rev 1998; 4: 121–8Google Scholar
  18. 18.
    Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001; 49: 597–606PubMedCrossRefGoogle Scholar
  19. 19.
    Medicines Commission Agency/Committee on Safety of Medicines. The safety of MMR vaccine. Curr Probl Pharmacovigilance 1999; 25: 9–10Google Scholar
  20. 20.
    Miller D, Wadsworth J, Diamond J, et al. Measles vaccination and neurological events. Lancet 1997; 349: 730–1PubMedCrossRefGoogle Scholar
  21. 21.
    Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351: 1327–8PubMedCrossRefGoogle Scholar
  22. 22.
    Halsey NA, Hyman SL, Conference Writing Panel. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunization Conference convened in Oak Brook, Illinois June 12–13, 2000. Pediatrics 2001; 107(5): E 84. Available from URL: http://www.pediatrics.org/cgi/content/full/107/5/e84 [Accessed 2001 Oct 23]CrossRefGoogle Scholar
  23. 23.
    Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass darkly. Adverse Drug React Toxicol Rev 2000; 19(4): 1–19Google Scholar
  24. 24.
    California Health and Human Services Agency (Department of Developmental Services). Changes in the population of persons with autism and pervasive developmental disorders in California’s developmental services system: 1987 through 1998. A report to the legislature, March 1, 1999. Sacramento (CA): California Health and Human Services Agency, 1999Google Scholar
  25. 25.
    Fombonne E. The epidemiology of autism. Psychol Med 1999; 29: 769–86PubMedCrossRefGoogle Scholar
  26. 26.
    Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand 1999; 99: 399–406PubMedCrossRefGoogle Scholar
  27. 27.
    Forsey T, Bentley ML, Minor PD, et al. Mumps vaccines and meningitis. Lancet 1992; 340: 980CrossRefGoogle Scholar
  28. 28.
    Kilroy AW, Schaffner W, Fleet Jr WF, et al. Two syndromes following rubella immunization: clinical observations and epidemiological studies. JAMA 1970; 214: 2287–92PubMedCrossRefGoogle Scholar
  29. 29.
    Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, editor. Pharmacoepidemiology. Chichester: John Wiley, 1994: 581–94Google Scholar
  30. 30.
    Stratton K, Gable A, Shetty P, McCormick M, editors. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, 2001Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.National Center on Birth Defects and Developmental DisabilitiesAtlantaUSA
  2. 2.Centers for Disease Control and PreventionNational Immunization ProgramAtlantaUSA

Personalised recommendations